Association of factor VII levels with inflammatory parameters in hypercholesterolemic patients

Atherosclerosis

Volumn 165, Issue 1, 2002, Pages 159-166

  Porreca, Ettore ^a   Di Febbo, Concetta ^a   Di Castelnuovo, Augusto ^b   Baccante, Giovanna ^a   Amore, Concetta ^b   Angelini, Antonio ^a   Di Nisio, Marcello ^a   Donati, Maria Benedetta ^b   Cuccurullo, Franco ^a   Iacoviello, Licia ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Factor VII; Hypercholesterolemia; Inflammation

Indexed keywords

ANTILIPEMIC AGENT; BLOOD CLOTTING FACTOR 7; C REACTIVE PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6 RECEPTOR; PADGEM PROTEIN; PRAVASTATIN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET; DISEASE MARKER; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; REGRESSION ANALYSIS; THROMBOGENESIS;

ADULT; AGED; ANALYSIS OF VARIANCE; BLOOD COAGULATION TESTS; COMBINED MODALITY THERAPY; CORONARY DISEASE; DIET, FAT-RESTRICTED; DRUG ADMINISTRATION SCHEDULE; FACTOR VII; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; INFLAMMATION MEDIATORS; LINEAR MODELS; MALE; MIDDLE AGED; PRAVASTATIN; PROBABILITY; REFERENCE VALUES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0036840659     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(02)00199-5     Document Type: Article

References (44)

1. Morrissey JH. Tissue factor and factor VII initiation of coagulation. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, editors. Haemostasis and Thrombosis. Basic Principles & Clinical Practice, Philadelphia, USA. Lippincott Williams & Wilkins 2001: 89-101.
2. Meade T.W., Ruddock V., Stirling Y., Chakrabarti R., Miller G.J. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 342:1993;1076-1079.
3. Heinrich J., Balleisen L., Schulte H., Assmann G., van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM Study in healthy men. Arterioscler. Thromb. 14:1994;54-59.
4. Hoffman C.J., Miller R.H., Lawson W.E., Hultin M.B. Elevation of factor VII activity and mass in young adults at risk of ischemic heart disease. J. Am. Coll. Cardiol. 14:1989;941-946.
5. Kario K., Matsuo T., Sakata T., Miyata T., et al. Factor VII hyperactivity and ischemic heart disease. Lancet. 343:1994;233.
6. Kario K., Sakata T., Matsuo T., Miyata T. Factor VII in non-insulin-dependent diabetic patients with microalbuminuria. Lancet. 342:1993;1552.
7. Junker R., Heinrich J., Schulte H., van de Loo J., Assmann G. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler. Thromb. Vasc. Biol. 17:1997;1539-1544.
8. Folsom A.R., Wu K.K., Rosamond W.D., Sharret R.A., Chambless L.E. Prospective study of hemostatic factors and incidence of coronary heart disease. Circulation. 96:1997;1102-1108.
9. Tracy R.P., Arnold A.M., Ettinger W., Fried L., Meilahn E., Savage P. The relationship of fibrinogen and factor VII and VIII to incident cardiovascular disease and death in the elderly. Results from the cardiovacular health study. Arterioscler. Thromb. Vasc. Biol. 19:1999;1776-1783.
10. Cooper J.A., Miller G.J., Bauer K.A., et al. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation. 102:2000;2816-2822.
11. Ridker P.M. Fibrinolytic and inflammatory markers for arterial occlusion: the evolving epidemiology of thrombosis and haemostasis. Thromb. Haemost. 78:1997;53-59.
12. Ridker P.M. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann. Intern. Med. 130:1999;933-937.
13. Ridker P.M., Glynn R.J., Hennekens C.H. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of the first myocardial infarction. Circulation. 97:1998;2007-2011.
14. Ridker P.M., Stampfer M.J., Rifai N. Novel risk factors for systemic atherosclerosis. A comparison of C-reactive protein, fibrinogen, homocysteine, lipoproteine (a), and standard cholesterol screening as predictors of peripheral arterial disease. J. Am. Med. Assoc. 285:2001;2481-2485.
15. Woodhouse P.R., Khaw K.T., Plummer M., Foley A., Meade T.W. Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease. Lancet. 343:1994;435-439.
16. Haverkate F., Thompson S.G., Duckett F. Haemostasic factors in angina pectoris; relation to gender, age, and acute-phase reaction. Results of the ECAT Angina Pectoris Study Group. Thromb. Haemost. 73:1995;561-567.
17. Horan J.T., Francis C.W., Falsey A.R., Kolassa J., Smith B.H., Hall W.J. Prothrombotic changes in hemostatic parameters and C-reactive protein in the elderly with winter acute respiratory tract infections. Thromb. Haemost. 85:2001;245-249.
18. Irish A.B., Gree F.R. Factor VII coagulant activity (VIIc) and hypercoagulability in chronic renal disease and dialysis: relationship with dyslipidaemia, inflammation, and factor VII genotype. Nephrol. Dial. Transplant. 13:1998;679-684.
19. Mezzano D., Pais E.O., Aranda E., et al. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int. 60:2001;1844-1850.
20. Baumann H., Gauldie J. The acute phase response. Immunol. Today. 15:1994;74-80.
21. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340:1999;448-454.
22. Hassan J.H., Chelucci C., Peschle C., Sorrentino V. Transforming growth factor β (TGF-β) inhibits expression of fibrinogen and factor VII in hepatoma cell line. Thromb. Haemost. 67:1992;478-483.
23. Ridker P.M., Hennekens C.H., Roitman-Johnson B., Stampfer M.J., Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risk of future myocardial infarction in apparently healthy men. Lancet. 351:1998;88-92.
24. Ridker P.M., Buring J.E., Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 103:2001;491-495.
25. National Cholesterol Education Program. Second Report of the Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adult (Adult Treatment Panel II). Circulation 1994;89:1329-1345.
26. Friedwald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of ultracentrifuge. Clin. Chim. Acta. 71:1972;397-402.
27. Van Waarde M.A.W.H., Van Assen A.J., Kampinga H.H., Konings A.W.T., Vuiaskovic Z. Quantification of Transforming growth factor-β in biological material using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal. Biochem. 247:1997;45-51.
28. SAS Institute Inc. SAS/STAT User Guide, Version 8.1. Cary, NC: SAS Institute Inc. 1989.
29. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340:1999;115-126.
30. Mennen L.I., Schouten E.G., Grobbee D.E., Kluff C. Coagulation factor VII, dietary fat and blood lipids: a review. Thromb. Haemost. 76:1996;492-499.
31. Griffin J.H., Fernandez J.A., Deguchi H. Plasma lipoproteins, haemostasis and thrombosis. Thromb. Haemost. 86:2001;386-394.
32. Iacoviello L., Vischetti M., Zito F., Donati M.B. Gene encoding fibrinogen and cardiovascular risk. Hypertension. 38:2001;1199-1203.
33. De Lange M., Snider H., Ariens A.S., Spector T.D., Grant P.J. The genetics of haemostasis: a twin study. Lancet. 357:2001;101-105.
34. Francis S.E., Camp N.J., Dewberry R.M., et al. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation. 99:1999;861-866.
35. Kohler H.P., Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N. Engl. J. Med. 342:2000;1792-1801.
36. Hackman A., Abe Y., Insull W., et al. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation. 93:1996;1334-1338.
37. Haverkate F., Thompson S.G., Pyke S.D., Gallimore J.R., Pepys M.B. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 349:1997;462-466.
38. Lindahl B., Toss H., Siegbahn A., Venge P., Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N. Engl. J. Med. 343:2000;1139-1147.
39. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and risks of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336:1997;973-979.
40. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342:2000;836-843.
41. Danesh J, Whincup P, Walker M et al. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses. Br Med J 2000;321:199-204.
42. Ridker P.M., Rifai N., Lowenthal S.P. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 103:2001;1191-1193.
43. Porreca E., Di Febbo C., Amore C., et al. Effect of lipid-lowering treatment on factor VII profile in hyperlipidemic patients. Thromb. Haemost. 84:2000;789-793.
44. Munford R.S. Statins and the acute-phase response. N. Engl. J. Med. 344:2001;2016-2018.